Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the ...

Human monoclonal antibodies derived from B cells of patients infected from the early SARS-CoV-2 variants and from vaccinated individuals are rapidly losing their efficacy with the emergence of new ...

Integral Molecular Uses Shotgun Mutagenesis to Germline-Humanize Monoclonal Antibodies Seventy percent of FDA-approved monoclonal antibodies (mAbs) and approximately 66% of mAbs currently in clinical ...

Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, ...

Monoclonal antibodies are highly specific for their antigen and have a well-characterized structure, making them ideal for use as antibody therapeutics. 5 Each mAb, composed of two heavy and two light ...

Ikoma, Japan – Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising ...